Skip to main content
. 2016 Nov 4;8(16):25897–25914. doi: 10.18632/oncotarget.13071

Figure 1. Rb1 and its metabolite compound K inhibit self-renewal and growth of CSCs.

Figure 1

A. The number of tumor spheres generated were photographed (left) and counted (right). In parallel experiments, cell viability was determined by MTT assay. The absorbance of wells not exposed to Rb1 or compound K (CK) treatment was arbitrarily set as 1, and cell growth after Rb1 or CK treatment was expressed as the fold changes compared to the control. B. Cell viability was determined after imatinib treatment. Bar, 50 μm. Experiments were repeated three times, and data are shown as mean ± SD. *, P < 0.05 vs control.